Merck Ends Nemtabrutinib Development Program
Merck has discontinued the clinical program for its investigational BTK inhibitor after an external review flagged risks outweighing benefits in a Phase 3 trial.
Updated on Nov. 17, 2026 in Cancer

Merck discontinued the clinical development program for nemtabrutinib (MK-1026), an investigational oral BTK inhibitor studied for chronic lymphocytic leukemia and other blood cancers. The company also stopped the broader BELLWAVE program, including Phase 3 trials BELLWAVE-008 and BELLWAVE-010.
Why it matters
An external Data Monitoring Committee suggested the benefits of nemtabrutinib may not outweigh its risks in the BELLWAVE-011 trial, and Merck confirmed that finding after reviewing the data in its totality. The decision removes one candidate from the pipeline of treatments being developed for leukemia and related blood cancers.
The discontinuation covers three Phase 3 trials, with the BELLWAVE-011 decision based on an external committee's risk-benefit assessment. Specific efficacy and safety figures were not released, and data analyses remain ongoing.
The players
Merck
Merck is a global pharmaceutical company headquartered in Rahway, New Jersey, that develops prescription medicines and vaccines.
The details
Merck announced on November 17, 2026, that it discontinued the clinical development program for nemtabrutinib, an investigational, oral, non-covalent Bruton's tyrosine kinase inhibitor being evaluated for chronic lymphocytic leukemia, small lymphocytic leukemia and other hematologic malignancies. The company stopped Phase 3 BELLWAVE-011 (NCT06136559) after its Data Monitoring Committee reviewed results, and it is informing study investigators of the decision for the BELLWAVE-008 and BELLWAVE-010 trials as well.
Timeline
November 17, 2026: Merck announces discontinuation of the nemtabrutinib clinical development program.
Health Landscape
Nemtabrutinib is a non-covalent BTK inhibitor, a newer approach than the covalent BTK inhibitors already used to treat chronic lymphocytic leukemia. Its discontinuation narrows the set of next-generation options being developed for blood cancers.
Patients with chronic lymphocytic leukemia will not have nemtabrutinib as a future treatment option from this program. Current treatment decisions remain with patients and their oncologists.
The takeaway
Pipeline setbacks like this one show that late-stage trials can be stopped when safety data outweigh expected benefits, which is why independent monitoring committees matter in cancer drug development.
Further reading
Explore more cancer research and treatment news for context on how targeted therapies are being developed.






